
Repligen Launches New TangenX SC Filtration Technology for Bioprocessing
11-2-23 (by: Scott Gleason) Repligen Corporation, a bioprocessing provider, has unveiled its new TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device for the production of biologics. The device is a fully closed system which is required by certain bioprocessing processes including the manufacturing processes for antibody drug conjugates (ADCs), viral vectors, nucleic acids, lipid nanoparticles, monoclonal antibodies, and recombinant proteins. TangenX SC represents an advanced flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF), processes integral to the purification and concentration of drugs in biopharmaceutical manufacturing.
Importantly, the holder-free design of TangenX SC and its simplified assembly have been shown to reduce setup time by up to 80%. The self-contained device eliminates holders and torquing requirements, thereby lowering the risk of product loss due to compression changes or cassette misalignment during installation. Additionally, the devices are versatile and can be scaled from pilot to process scale. Designed with the same flow path length and channel geometry as traditional cassettes, TangenX SC allows users to transition without disruption. TangenX SC devices are also aseptically closed and gamma irradiated, reducing the risk of bioburden contamination and enabling their use in Controlled not Classified (CNC) manufacturing environments. The closed design enhances operator safety by isolating them from potentially hazardous materials.
Christine Gebski, Senior Vice President of Filtration and Chromatography at Repligen, praised the innovative TangenX SC, stating, “TangenX SC pushes the boundaries of TFF innovation, offering clear advantages to virtually any user of flat sheet TFF. The holder-free TangenX SC device simplifies and streamlines downstream flat sheet UF/DF processes like never before. Users can trust that the quality and consistency of their TFF processes remain uncompromised while enjoying the benefits of this innovative technology.”